Journal of Medical Toxicology

, Volume 15, Issue 3, pp 184–191 | Cite as

Adverse Effects of Physostigmine

  • Ann M. ArensEmail author
  • Tom Kearney



Physostigmine is a tertiary amine carbamate acetylcholinesterase inhibitor. Its ability to cross the blood-brain barrier makes it an effective antidote to reverse anticholinergic delirium. Physostigmine is underutilized following the publication of patients with sudden cardiac arrest after physostigmine administration in patients with tricyclic antidepressant (TCA) overdoses. We completed a narrative literature review to identify reported adverse effects associated with physostigmine administration.


One hundred sixty-one articles and a total of 2299 patients were included. Adverse effects occurred in 415 (18.1%) patients. Hypersalivation (206; 9.0%) and nausea and vomiting (96; 4.2%) were the most common adverse effects. Fifteen (0.61%) patients had seizures, all of which were self-limited or treated successfully without complication. Symptomatic bradycardia occurred in 8 (0.35%) patients including 3 patients with bradyasystolic arrests. Ventricular fibrillation occurred in one (0.04%) patient with underlying coronary artery disease. Of the 394 patients with TCA overdose, adverse effects were described in 14 (3.6%). Adverse effects occurred in 7.7% of patients treated with an overdose of an anticholinergic agent compared with 20.6% of patients with non-anticholinergic agents. Five (0.22%) fatalities were identified.


In conclusion, significant adverse effects associated with the use of physostigmine were infrequently reported. Seizures were self-limited or resolved with benzodiazepines, and all patients recovered neurologically intact. Physostigmine should be avoided in patients with QRS prolongation on EKG, and caution should be used in patients with a history of coronary artery disease and overdoses with QRS prolonging medications. Based upon our review, physostigmine is a safe antidote to treat anticholinergic overdose.


Physostigmine Antidote Antimuscarinic Delirium Review 


Sources of Funding


Compliance with Ethical Standards

Conflicts of Interest


Supplementary material

13181_2019_697_MOESM1_ESM.docx (141 kb)
ESM 1 (DOCX 100 kb)


  1. 1.
    Pentel P, Peterson CD. Asystole complicating physostigmine treatment of tricyclic antidepressant overdose. Ann Emerg Med. 1980;9(11):588–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Watkins JW, Schwarz ES, Arroyo-Plasencia AM, Mullins ME. Toxicology Investigators Consortium i. The use of physostigmine by toxicologists in anticholinergic toxicity. J Med Toxicol. 2015;11(2):179–84. Scholar
  3. 3.
    Burns MJ, Linden CH, Graudins A, Brown RM, Fletcher KE. A comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning. Ann Emerg Med. 2000;35(4):374–81.CrossRefPubMedGoogle Scholar
  4. 4.
    Triggle DJ, Mitchell JM, Filler R. The pharmacology of physostigmine. CNS Drug Reviews. 1998;4(2):87–136. Scholar
  5. 5.
    Rumack BH. Anticholinergic poisoning: treatment with physostigmine. Pediatrics. 1973;52(3):449–51.PubMedGoogle Scholar
  6. 6.
    Nilsson E, Meretoja OA, Neuvonen P. Hemodynamic responses to physostigmine in patients with a drug overdose. Anesth Analg. 1983;62(10):885–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Larson GF, Hurlbert BJ, Wingard DW. Physostigmine reversal of diazepam-induced depression. Anesth Analg. 1977;56(3):348–51.CrossRefPubMedGoogle Scholar
  8. 8.
    Weinstock M, Davidson JT, Rosin AJ, Schnieden H. Effect of physostigmine on morphine-induced postoperative pain and somnolence. Br J Anaesth. 1982;54(4):429–34.CrossRefPubMedGoogle Scholar
  9. 9.
    Hartvig P, Wiklund L, Lindstrom B. Pharmacokinetics of physostigmine after intravenous, intramuscular and subcutaneous administration in surgical patients. Acta Anaesthesiol Scand. 1986;30(2):177–82.CrossRefPubMedGoogle Scholar
  10. 10.
    Schneck HJ, Rupreht J. Central anticholinergic syndrome (CAS) in anesthesia and intensive care. Acta Anaesthesiol Belg. 1989;40(3):219–28.PubMedGoogle Scholar
  11. 11.
    Rupreht J, Dworacek B, Oosthoek H, Dzoljic MR, Valkenburg M. Physostigmine versus naloxone in heroin-overdose. J Toxicol Clin Toxicol. 2008;21(3):387–97. Scholar
  12. 12.
    Caldicott DG, Kuhn M. Gamma-hydroxybutyrate overdose and physostigmine: teaching new tricks to an old drug? Ann Emerg Med. 2001;37(1):99–102. Scholar
  13. 13.
    Asthana S, Greig NH, Hegedus L, Holloway HH, Raffaele KC, Schapiro MB, et al. Clinical pharmacokinetics of physostigmine in patients with Alzheimer’s disease. Clin Pharmacol Ther. 1995;58(3):299–309. Scholar
  14. 14.
    Cumming G, Harding LK, Prowse K. Treatment and recovery after massive overdose of physostigmine. Lancet. 1968;2(7560):147–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Salas R, Cook KD, Bassetto L, De Biasi M. The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice. Neuropharmacology. 2004;47(3):401–7. Scholar
  16. 16.
    Gholami M, Saboory E, Zare S, Roshan-Milani S, Hajizadeh-Moghaddam A. The effect of dorsal hippocampal administration of nicotinic and muscarinic cholinergic ligands on pentylenetetrazol-induced generalized seizures in rats. Epilepsy Behav. 2012;25(2):244–9. Scholar
  17. 17.
    Trivisano M, Terracciano A, Milano T, Cappelletti S, Pietrafusa N, Bertini ES, et al. Mutation of CHRNA2 in a family with benign familial infantile seizures: potential role of nicotinic acetylcholine receptor in various phenotypes of epilepsy. Epilepsia. 2015;56(5):e53–7. Scholar
  18. 18.
    Holinger PC, Klawans HL. Reversal of tricyclic-overdosage-induced central anticholinergic syndrome by physostigmine. Am J Psychiatry. 1976;133(9):1018–23. Scholar
  19. 19.
    Burks JS, Walker JE, Rumack BH, Ott JE. Tricyclic antidepressant poisoning. Reversal of coma, choreoathetosis, and myoclonus by physostigmine. JAMA. 1974;230(10):1405–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Suchard JR. Assessing physostigmine’s contraindication in cyclic antidepressant ingestions. J Emerg Med. 2003;25(2):185–91. Scholar
  21. 21.
    Magera BE, Betlach CJ, Sweatt AP, Derrick CW Jr. Hydroxyzine intoxication in a 13-month-old child. Pediatrics. 1981;67(2):280–3.PubMedGoogle Scholar
  22. 22.
    Eyer F, Pfab R, Felgenhauer N, Strubel T, Saugel B, Zilker T. Clinical and analytical features of severe suicidal quetiapine overdoses--a retrospective cohort study. Clin Toxicol (Phila). 2011;49(9):846–53. Scholar
  23. 23.
    Newton RW. Physostigmine salicylate in the treatment of tricyclic antidepressant overdosage. JAMA. 1975;231(9):941–3.CrossRefPubMedGoogle Scholar
  24. 24.
    Stewart GO. Convulsions after physostigmine. Anaesth Intensive Care. 1979;7(3):283.CrossRefPubMedGoogle Scholar
  25. 25.
    Tobis J, Das BN. Cardiac complications in amitriptyline poisoning. Successful treatment with physostigmine. JAMA. 1976;235(14):1474–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Schneir AB, Offerman SR, Ly BT, Davis JM, Baldwin RT, Williams SR, et al. Complications of diagnostic physostigmine administration to emergency department patients. Ann Emerg Med. 2003;42(1):14–9. Scholar
  27. 27.
    Rasimas JJSK, Donovan JW. Revival of an antidote: bedside experience with physostigmine. J Am Assoc Emerg Psychiatry. 2014;12(2):5–24.Google Scholar
  28. 28.
    Artru AA, Hui GS. Physostigmine reversal of general anesthesia for intraoperative neurological testing: associated EEG changes. Anesth Analg. 1986;65(10):1059–62.CrossRefPubMedGoogle Scholar
  29. 29.
    Bidwai AV, Cornelius LR, Stanley TH. Reversal of innovar-induced postanesthetic somnolence and disorientation with physostigmine. Anesthesiology. 1976;44(3):249–52.CrossRefPubMedGoogle Scholar
  30. 30.
    Holzgrafe RE, Vondrell JJ, Mintz SM. Reversal of postoperative reactions to scopolamine with physostigmine. Anesth Analg. 1973;52(6):921–5.CrossRefPubMedGoogle Scholar
  31. 31.
    Avant GR, Speeg KV Jr, Freemon FR, Schenker S, Berman ML. Physostigmine reversal of diazepam-induced hypnosis. A study in human volunteers. Ann Intern Med. 1979;91(1):53–5.CrossRefPubMedGoogle Scholar
  32. 32.
    Gillick JS. Atropine toxicity in a neonate. Br J Anaesth. 1974;46(10):793–4.CrossRefPubMedGoogle Scholar
  33. 33.
    Henderson RS, Holmes CM. Reversal of the anaesthetic action of sodium gamma-hydroxybutyrate. Anaesth Intensive Care. 1976;4(4):351–4.CrossRefPubMedGoogle Scholar
  34. 34.
    Shannon M. Toxicology reviews: physostigmine. Pediatr Emerg Care. 1998;14(3):224–6.CrossRefPubMedGoogle Scholar
  35. 35.
    Kulig K, Rumack BH. Physostigmine and asystole. Ann Emerg Med. 1981;10(4):228–0.CrossRefPubMedGoogle Scholar
  36. 36.
    Kolecki PF, Curry SC. Poisoning by sodium channel blocking agents. Crit Care Clin. 1997;13(4):829–48.CrossRefPubMedGoogle Scholar
  37. 37.
    Zvosec DL, Smith SW, Litonjua R, Westfal RE. Physostigmine for gamma-hydroxybutyrate coma: inefficacy, adverse events, and review. Clin Toxicol (Phila). 2007;45(3):261–5. Scholar
  38. 38.
    Maister AH. Atrial fibrillation following physostigmine. Can Anaesth Soc J. 1983;30(4):419–21.CrossRefPubMedGoogle Scholar
  39. 39.
    Danze LK, Langdorf MI. Reversal of orphenadrine-induced ventricular tachycardia with physostigmine. J Emerg Med. 1991;9(6):453–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Schmidt W, Lang K. Life-threatening dysrhythmias in severe thioridazine poisoning treated with physostigmine and transient atrial pacing. Crit Care Med. 1997;25(11):1925–30.CrossRefPubMedGoogle Scholar
  41. 41.
    Wright SP. Usefulness of physostigmine in imipramine poisoning. A dramatic response in a child resistant to other therapy. Clin Pediatr (Phila). 1976;15(12):1123–8. Scholar
  42. 42.
    Greene LT. Physostigmine treatment of anticholinergic-drug depression in postoperative patients. Anesth Analg. 1971;50(2):222–6.CrossRefPubMedGoogle Scholar
  43. 43.
    Boon J, Prideaux PR. Cardiac arrest following physostigmine. Anaesth Intensive Care. 1980;8(1):92–3.CrossRefPubMedGoogle Scholar
  44. 44.
    Mogelnicki SR, Waller JL, Finlayson DC. Physostigmine reversal of cimetidine--induced mental confusion. JAMA. 1979;241(8):826–7.CrossRefPubMedGoogle Scholar
  45. 45.
    Ryan R 3rd, Wians FH Jr, Stigelman WH Jr, Clark H, McCurdy F. Imipramine poisoning in a child: lack of efficacy of resin hemoperfusion. Pediatr Emerg Care. 1985;1(4):201–4.CrossRefPubMedGoogle Scholar
  46. 46.
    Ordiway MV. Treating tricyclic overdose with physostigmine. Am J Psychiatry. 1978;135(9):1114.CrossRefPubMedGoogle Scholar
  47. 47.
    Bigger JT Jr, Kantor SJ, Glassman AH, Perel JM. Is physostigmine effective for cardiac toxicity of tricyclic antidepressant drugs. JAMA. 1977;237(13):1311.CrossRefPubMedGoogle Scholar
  48. 48.
    Saadeh AM, Farsakh NA, Al-Ali MK. Cardiac manifestations of acute carbamate and organophosphate poisoning. Heart. 1997;77(5):461–4.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Linz D, Elliott AD, Hohl M, Malik V, Schotten U, Dobrev D, et al. Role of autonomic nervous system in atrial fibrillation. Int J Cardiol. 2018.
  50. 50.
    May AE, Machin JR, Wyatt R. Physostigmine in open-heart surgery. Reversal of hyoscine supplementation of morphine-oxygen-air-relaxant anaesthesia. Anaesthesia. 1978;33(6):547–50.CrossRefPubMedGoogle Scholar

Copyright information

© American College of Medical Toxicology 2019

Authors and Affiliations

  1. 1.Minnesota Poison Control SystemMinneapolisUSA
  2. 2.Hennepin Healthcare, Department of Emergency MedicineHennepin County Medical CenterMinneapolisUSA
  3. 3.California Poison Control System, San Francisco DivisionSan FranciscoUSA
  4. 4.San Francisco School of PharmacyUniversity of CaliforniaSan FranciscoUSA

Personalised recommendations